Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 4/20 | 0.33 |
| ▸ | ANPEP | P15144 | 3/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8983770 | 1.00 | TSHR (0.36) | TSHRMMP2ANPEPATMMEN1 | |
| SCHEMBL6798706 | 1.00 | TSHR (0.36) | TSHRMMP2ANPEPATMMEN1 | |
| SCHEMBL3307394 | 1.00 | TSHR (0.36) | TSHRMMP2ANPEPATMMEN1 | |
| SCHEMBL8866598 | 0.90 | MMP2 (0.39) | TSHRMMP2ANPEP | |
| SCHEMBL8867224 | 0.90 | MMP2 (0.39) | TSHRMMP2ANPEP | |
| SCHEMBL13390232 | 0.89 | TSHR (0.36) | TSHRMMP2ANPEPTHRB | |
| SCHEMBL3304315 | 0.87 | HSD17B10 (0.38) | — | |
| SCHEMBL3301971 | 0.87 | HSD17B10 (0.38) | — | |
| SCHEMBL6607994 | 0.86 | AGTR2 (0.35) | TSHRMEN1KMT2A | |
| SCHEMBL25475425 | 0.84 | ALDH1A1 (0.32) | TSHRMMP2ANPEPKMT2ATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074887-A1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF | Sea Pharmaceuticals LLC. (US) | 2025-03-06 | — | — | US | disclosed |
| US-20100094014-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | MARTINEZ-PEREZ JOSE ANTONIO | 2010-04-15 | — | — | US | disclosed |
| EP-2166003-A1 | Excitatory amino acid receptor antagonists | Eli Lilly & Company (US) | 2010-03-24 | — | — | EP | disclosed |
| US-7601738-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1368032-B1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-06-11 | — | — | EP | disclosed |
| US-7205313-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-20060100237-A1 | Excitatory amino acid receptor antagonists | ARNOLD MACKLIN B | 2006-05-11 | — | — | US | disclosed |
| US-6953805-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2005-10-11 | — | — | US | disclosed |
| US-20050170999-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | FILLA SANDRA A (US) | 2005-08-04 | — | — | US | disclosed |
| US-6924294-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2005-08-02 | — | — | US | disclosed |
| US-5670516-A | NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1997-09-23 | — | — | US | disclosed |
| US-5648492-A | Process for preparing isoquinoline compounds | ELI LILLY AND COMPANY (US) | 1997-07-15 | — | — | US | disclosed |
| US-5637712-A | CATALYTIC HYDROGENNATION | ELI LILLY AND COMPANY (US) | 1997-06-10 | — | — | US | disclosed |
| US-5606062-A | STEREOSELECTIVE REDUCTION | ELI LILLY AND COMPANY (US) | 1997-02-25 | — | — | US | disclosed |
| US-5527810-A | USEFUL IN THE TREATMENT OF NEUROLOGICAL DISORDERS | ELI LILLY AND COMPANY (US) | 1996-06-18 | — | — | US | disclosed |
| US-5446051-A | Nervous system disorder and brain disorder | ELI LILLY AND COMPANY (US) | 1995-08-29 | — | — | US | disclosed |
| US-5399696-A | Excitatory amino acid receptor antagonists; nervous system disorders | ELI LILLY AND COMPANY (US) | 1995-03-21 | — | — | US | disclosed |
| US-5356902-A | Central nervous system disorders | ELI LILLY AND COMPANY (US) | 1994-10-18 | — | — | US | disclosed |
| EP-0590789-A1 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1994-04-06 | — | — | EP | disclosed |
| US-5284957-A | Substituted 1H- or 2H-tetrazoles | ELI LILLY AND COMPANY (US) | 1994-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074887-A1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF | GABRQ, GRIK5, CYP3A7 | TSHR 3434/4885MMP2 2337/4885ANPEP 2525/4885 |
| US-20100094014-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | SLC1A2, SLC1A1, GRIN1 | TSHR 642/4885MMP2 4471/4885ANPEP 668/4885 |
| US-20050170999-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | SLC1A2, SLC1A1, SLC1A3 | TSHR 807/4885MMP2 4107/4885ANPEP 787/4885 |
| US-20060100237-A1 | Excitatory amino acid receptor antagonists | SLC1A2, SLC1A1, GRIN1 | TSHR 642/4885MMP2 4471/4885ANPEP 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.